| Code | CSB-RA002831MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Mertuzumab, targeting BSG (basigin), also known as CD147 or EMMPRIN (extracellular matrix metalloproteinase inducer). BSG is a transmembrane glycoprotein belonging to the immunoglobulin superfamily that plays critical roles in multiple cellular processes including stimulation of matrix metalloproteinase production, regulation of monocarboxylate transporters, and facilitation of cell-cell interactions. The protein is highly expressed in various malignancies and has been implicated in tumor progression, metastasis, angiogenesis, and drug resistance. BSG also serves as a receptor for certain pathogens and is involved in inflammatory responses, making it a significant target in cancer biology and infectious disease research.
Mertuzumab, the reference antibody for this biosimilar, was developed to target BSG-expressing tumors and has been investigated in oncology research settings. This biosimilar antibody provides researchers with a valuable tool for investigating BSG-mediated signaling pathways, exploring therapeutic targeting strategies, and studying the protein's role in tumor microenvironment interactions and metabolic regulation across various disease models.
There are currently no reviews for this product.